title: Lung volumes and respiratory muscle strength in adult patients with childhood- or adult-onset growth hormone deficiency: effect of 12 months' growth hormone replacement therapy.
abstract: We have described impairment of the respiratory function in adult patients with childhood-onset growth hormone (GH) deficiency. The aim of the present study was to evaluate lung volumes and respiratory muscle strength in patients diagnosed as GH deficient before and after 6 and 12 months of recombinant GH treatment. Ten adults diagnosed as GH deficient in childhood, ten adults diagnosed as GH deficient in adulthood and ten healthy subjects entered the study. For each subject, evaluation of respiratory function followed the same standard approach, consisting of respiratory muscle strength assessment, record of flow-volume curves, measurement of static lung volumes and lung diffusing capacity. Childhood-onset GH-deficient patients had a significant reduction of maximal inspiratory (p < 0.01) and maximal expiratory (p < 0.05) mouth pressures. Total lung capacity, vital capacity and functional residual capacity were significantly reduced compared to healthy subjects (p < 0.05). Conversely, residual volume and diffusing lung capacity did not show any significant change. No significant change of the ratio between the percentage forced expiratory volume in 1 s and the forced vital capacity was observed. The decrease of respiratory mouth pressures was not correlated to the decrease of lung volumes. Adult-onset GH-deficient patients had only a significant reduction of maximal expiratory pressure compared to healthy subjects (p < 0.05). After 6 months of treatment no significant differences in any of the evaluated parameters were found. After 12 months of treatment patients with childhood-onset GH deficiency show a significant improvement of lung volumes (p < 0.01) and maximal respiratory mouth pressures (p < 0.005), whereas adult-onset GH-deficient patients show a significant improvement of maximal expiratory pressure (p < 0.05). In conclusion, the results of this study showed that adult patients affected with childhood-onset GH deficiency suffer from an impairment of the ventilatory function due to a reduction of lung volumes and a decrease of respiratory pressures probably due to a reduction of respiratory muscle strength. This impairment was reversed after 12 months of treatment with recombinant GH. Conversely, adult-onset GH-deficient patients had only an impairment of the maximal expiratory pressure, probably due to respiratory muscle weakness re-established after 12 months of GH therapy.
authors.affiliation: Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Naples, Italy.
authors.forename: B
authors.initials: B
authors.lastname: Merola
authors.forename: S
authors.initials: S
authors.lastname: Longobardi
authors.forename: M
authors.initials: M
authors.lastname: Sofia
authors.forename: R
authors.initials: R
authors.lastname: Pivonello
authors.forename: A
authors.initials: A
authors.lastname: Micco
authors.forename: F
authors.initials: F
authors.lastname: Di Rella
authors.forename: V
authors.initials: V
authors.lastname: Esposito
authors.forename: A
authors.initials: A
authors.lastname: Colao
authors.forename: G
authors.initials: G
authors.lastname: Lombardi
mesh_terms: D000328:Adult; D017668:Age of Onset; D005260:Female; D006728:Hormones / Q000097:blood; D019382:Human Growth Hormone / Q000172:deficiency* / Q000627:therapeutic use*; D006801:Humans; D008168:Lung / Q000503:physiopathology*; D008176:Lung Volume Measurements; D008297:Male; D011994:Recombinant Proteins; D012119:Respiration; D012132:Respiratory Muscles / Q000503:physiopathology*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D006728:Hormones; D011994:Recombinant Proteins; D019382:Human Growth Hormone